多发性骨髓瘤CAR-T细胞疗法的开发进展
本文综述了多发性骨髓瘤(MM)CAR-T细胞疗法的现状,涵盖靶点、设计与开发阶段。针对B细胞成熟抗原的自体CAR-T细胞疗法目前证据最佳,但缓解持续时间、长期随访、 prolonged cytopenia、髓外病变患者获益、结局预测及治疗范式整合等问题尚待解决。其他有前景的靶点包括CD38、SLAMF7/CS1和GPRC5D。
要点
- 针对BCMA的自体CAR-T细胞疗法在 heavily pretreated MM 患者中显示疗效且毒性可控,但缓解持续时间等问题待解决。
- 其他有前景的靶点包括CD38、SLAMF7/CS1和GPRC5D。
- 目前尚无产品获批,成本和制备时间是自体产品广泛使用的主要障碍,异基因CAR-T细胞正在探索中。
核心结论
- 针对BCMA的自体CAR-T细胞疗法目前证据最佳,但缓解持续时间、长期随访、 prolonged cytopenia、髓外病变患者获益、结局预测及CAR-T细胞疗法在MM治疗范式中的整合等主要问题尚待解决。
- 尽管目前尚无产品获批,但成本和制备时间预计是自体产品广泛使用的主要障碍,因此正在探索异基因CAR-T细胞。
- 异基因CAR-T细胞固有的移植物抗宿主病风险需要额外修饰,这些修饰仍需验证。
研究设计与样本
- 本文为综述,旨在呈现MM中CAR-T细胞疗法的现状,概述当前靶点、设计和CAR-T细胞开发阶段。
- MM中CAR-T领域正在快速演变,目前有超过50项正在进行的临床试验,涵盖所有阶段、不同CAR-T设计或靶点。
- 大多数CAR-T试验在中国和美国进行,而欧洲中心仅组织或参与当前临床研究的一小部分。
主要发现
- 针对B细胞成熟抗原的自体CAR-T细胞疗法显示出最佳疗效证据。
- 其他有前景的靶点包括CD38、SLAMF7/CS1和GPRC5D。
- 目前尚无产品获批。
关键数值与推荐
- 目前有超过50项正在进行的临床试验,涵盖所有阶段、不同CAR-T设计或靶点。
- 大多数CAR-T试验在中国和美国进行,欧洲中心仅组织或参与当前临床研究的一小部分。
临床怎么用
- 原文未据此给出推荐。
局限性
- 缓解持续时间、长期随访、 prolonged cytopenia、髓外病变患者获益、结局预测及CAR-T细胞疗法在MM治疗范式中的整合等主要问题尚待解决。
- 异基因CAR-T细胞固有的移植物抗宿主病风险需要额外修饰,这些修饰仍需验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Currently available data on chimeric antigen receptor (CAR)-T cell therapy has demonstrated efficacy and manageable toxicity in heavily pretreated multiple myeloma (MM) patients. The CAR-T field in MM is rapidly evolving with >50 currently ongoing clinical trials across all phases, different CAR-T design, or targets. Most of the CAR-T trials are performed in China and the United States, while European centers organize or participate in only a small fraction of current clinical investigations. Autologous CAR-T cell therapy against B cell maturation antigen shows the best evidence of efficacy so far but main issues remain to be addressed: duration of response, longer follow-up, prolonged cytopenia, patients who may benefit the most such as those with extramedullary disease, outcome prediction, and the integration of CAR-T cell therapy within the MM treatment paradigm. Other promising targets are, i.a.,: CD38, SLAMF7/CS1, or GPRC5D. Although no product has been approved to date, cost and production time for autologous products are expected to be the main obstacles for broad use, for which reason allogeneic CAR-T cells are currently explored. However, the inherent risk of graft-versus-host disease requires additional modification which still need to be validated. This review aims to present the current status of CAR-T cell therapy in MM with an overview on current targets, designs, and stages of CAR-T cell development. Main challenges to CAR-T cell therapy will be highlighted as well as strategies to structurally improve the CAR-T cell product, and thereby its efficacy and safety. The need for comparability of the most promising therapies will be emphasized to balance risks and benefits in an evidence-based but personalized approach to further improve outcome of patients with MM.
引用
- Gagelmann N, Riecken K, Wolschke C, et al. Development of CAR-T cell therapies for multiple myeloma. Leukemia. 2020. PMID: 32572190. doi:10.1038/s41375-020-0930-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。